ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Enliven Therapeutics Inc

Enliven Therapeutics Inc (ELVN)

21,195
-0,355
( -1,65% )
Aktualisiert: 16:22:11

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Current Price
21,195
Gebot
21,05
Fragen
21,31
Volumen
23.372
20,8165 Tagesbereich 21,82
10,9001 52-Wochen-Bereich 30,03
Marktkapitalisierung
Handelsende
21,55
Handelsbeginn
21,20
Letzte Trade
2
@
21.129
Letzter Handelszeitpunkt
16:21:57
Finanzvolumen
US$ 497.592
VWAP
21,2901
Durchschnittliches Volumen (3 Mio.)
221.559
Ausgegebene Aktien
48.859.166
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-4,31
Gewinn pro Aktie (EPS)
-1,47
Erlöse
-
Nettogewinn
-71,58M

Über Enliven Therapeutics Inc

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. The Company focuses on addressing existing and emerging unmet needs with a precision oncology approach. The Company is advancin... Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. The Company focuses on addressing existing and emerging unmet needs with a precision oncology approach. The Company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, as well as pursuing several additional research stage opportunities. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). Its second product candidate, ELVN-002, is a potent, selective, and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against various HER2 mutations, including Exon 20 insertion mutations (E20IMs) in non-small cell lung cancer (NSCLC). Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Enliven Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ELVN. The last closing price for Enliven Therapeutics was US$21,55. Over the last year, Enliven Therapeutics shares have traded in a share price range of US$ 10,9001 to US$ 30,03.

Enliven Therapeutics currently has 48.859.166 shares in issue. The market capitalisation of Enliven Therapeutics is US$1,05 billion. Enliven Therapeutics has a price to earnings ratio (PE ratio) of -4.31.

ELVN Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.745-3.3956244302621.9423.1820.816519189522.24727342CS
4-0.985-4.4409377817922.1823.1820.1627196621.70059394CS
12-3.705-14.879518072324.926.4820.1622155922.88688483CS
26-0.135-0.63291139240521.3330.0320.1623073824.51699442CS
525.35533.806818181815.8430.0310.900125782922.68068493CS
156-3.005-12.417355371924.230.039.820368420.83039446CS
260-3.005-12.417355371924.230.039.820368420.83039446CS

ELVN - Frequently Asked Questions (FAQ)

What is the current Enliven Therapeutics share price?
The current share price of Enliven Therapeutics is US$ 21,195
How many Enliven Therapeutics shares are in issue?
Enliven Therapeutics has 48.859.166 shares in issue
What is the market cap of Enliven Therapeutics?
The market capitalisation of Enliven Therapeutics is USD 1,05B
What is the 1 year trading range for Enliven Therapeutics share price?
Enliven Therapeutics has traded in the range of US$ 10,9001 to US$ 30,03 during the past year
What is the PE ratio of Enliven Therapeutics?
The price to earnings ratio of Enliven Therapeutics is -4,31
What is the reporting currency for Enliven Therapeutics?
Enliven Therapeutics reports financial results in USD
What is the latest annual profit for Enliven Therapeutics?
The latest annual profit of Enliven Therapeutics is USD -71,58M
What is the registered address of Enliven Therapeutics?
The registered address for Enliven Therapeutics is CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
Which industry sector does Enliven Therapeutics operate in?
Enliven Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
BHATBlue Hat Interactive Entertainment Technology
US$ 0,128351
(86,02%)
599,77M
AIFFFirefly Neuroscience Inc
US$ 5,04
(62,58%)
49,76M
OCEAOcean Biomedical Inc
US$ 0,2373
(60,34%)
289,15M
DOMHDominari Holdings Inc
US$ 8,36
(35,71%)
21,41M
CYNCYNGN Inc
US$ 0,2492
(34,92%)
477,15M
FLNCFluence Energy Inc
US$ 6,8099
(-47,90%)
21,37M
FTELFitell Corporation
US$ 1,26
(-41,40%)
1,33M
CMCOColumbus McKinnon Corporation
US$ 20,97
(-40,90%)
888,52k
LIXTLixte Biotechnology Holdings Inc
US$ 1,47
(-35,53%)
1,38M
HYPRHyperfine Inc
US$ 1,105
(-33,83%)
1,81M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,1287
(86,52%)
599,77M
CYNCYNGN Inc
US$ 0,2499
(35,30%)
477,39M
OCEAOcean Biomedical Inc
US$ 0,236
(59,46%)
289,15M
INABIN8bio Inc
US$ 0,349
(29,21%)
159,21M
MGOLMGO Global Inc
US$ 0,5134
(-26,62%)
61,29M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock